









Markets
/
Stocks
/
nasdaq-otlk
/

Outlook Therapeutics Inc

OTLK

0.429USD

+0.039+10.10%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

23.14MMarket Cap

LossP/E TTM



Outlook Therapeutics Inc

0.429

+0.039+10.10%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Outlook Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Outlook Therapeutics Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 200 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.38.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Outlook Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

200 / 392

Overall Ranking

388 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Outlook Therapeutics Inc Highlights

StrengthsRisks

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.41M.

Overvalued

The company’s latest PE is -0.24, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 4.34M shares, decreasing 70.98% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.47M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.63.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

5.375

Target Price

+1243.75%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Outlook Therapeutics Inc is 5.75, ranking 330 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.72

Change

0.03



Financials

6.03

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.08

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.94

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Outlook Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Outlook Therapeutics Inc is 8.28, ranking 52 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.24, which is -307.64% below the recent high of 0.50 and -3081.16% above the recent low of -7.62.

Score

Industry at a Glance

Previous score

8.28

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 200/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Outlook Therapeutics Inc is 7.00, ranking 311 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 21.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

5.375

Target Price

+1243.75%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Outlook Therapeutics Inc

OTLK

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Outlook Therapeutics Inc is 2.57, ranking 375 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.59 and the support level at 0.32, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.44

Change

0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.076

Neutral

RSI(14)

27.315

Sell

STOCH(KDJ)(9,3,3)

19.681

Buy

ATR(14)

0.040

Low Volatility

CCI(14)

-86.610

Neutral

Williams %R

69.360

Sell

TRIX(12,20)

-4.270

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

0.418

Buy

MA10

0.444

Sell

MA20

0.491

Sell

MA50

1.230

Sell

MA100

1.260

Sell

MA200

1.525

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Outlook Therapeutics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 5.90%, representing a quarter-over-quarter decrease of 57.09%. The largest institutional shareholder is The Vanguard, holding a total of 1.47M shares, representing 1.99% of shares outstanding, with 21.68% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

GMS Ventures and Investments

13.55M

+46.25%

The Vanguard Group, Inc.

Star Investors

1.34M

+7.27%

Schonfeld Strategic Advisors LLC

715.17K

-47.60%

BlackRock Institutional Trust Company, N.A.

365.34K

+10.62%

Geode Capital Management, L.L.C.

306.30K

+15.31%

Susquehanna International Group, LLP

211.42K

+79.52%

Millennium Management LLC

194.58K

-42.53%

Commonwealth Financial Network

113.15K

+301.94%

BofA Global Research (US)

90.47K

+1058.01%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Outlook Therapeutics Inc is 1.41, ranking 318 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -0.05. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Outlook Therapeutics Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.